US FDA approves Durysta™ (bimatoprost implant) intracameral sustained-release implant to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension

The approval was based on results from the two 20-month (including 8-month extended follow up) Phase 3 ARTEMIS studies, in which it was shown to be statistically non-inferior to twice daily topical timolol drops in terms of reduction in intraocular pressure versus baseline.


Biospace Inc.